Roger Song
Stock Analyst at Jefferies
(3.78)
# 695
Out of 5,124 analysts
51
Total ratings
47.73%
Success rate
11.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Buy | $95 → $118 | $84.49 | +39.66% | 1 | Feb 2, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $13 → $42 | $20.46 | +105.28% | 3 | Jan 22, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $36.81 | +228.72% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $33.05 | +36.16% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $7.88 | +103.05% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $485.36 | +16.20% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.22 | +309.84% | 1 | Aug 28, 2025 | |
| ATYR aTyr Pharma | Maintains: Buy | $9 → $17 | $0.90 | +1,790.99% | 2 | Aug 22, 2025 | |
| MBX MBX Biosciences | Assumes: Buy | $36 | $37.67 | -4.43% | 1 | Aug 15, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $54 | $43.09 | +25.32% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $6 | $7.75 | -22.58% | 2 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.39 | +331.65% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.93 | +78.12% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $245 | $272.74 | -10.17% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $13.45 | +93.31% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $42 → $7 | $20.73 | -66.23% | 2 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $7.83 | +257.60% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $3.57 | +96.08% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $79.72 | +11.64% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $8.25 | +203.03% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $16.85 | +143.32% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $21.80 | +60.55% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $56.15 | +129.74% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $5.67 | +41.09% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $103.59 | -6.36% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $28.44 | +286.78% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $4.87 | +618.69% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $2.17 | +314.75% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $15.52 | +1,253.09% | 1 | Sep 2, 2020 |
Protagonist Therapeutics
Feb 2, 2026
Maintains: Buy
Price Target: $95 → $118
Current: $84.49
Upside: +39.66%
Corvus Pharmaceuticals
Jan 22, 2026
Maintains: Buy
Price Target: $13 → $42
Current: $20.46
Upside: +105.28%
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $36.81
Upside: +228.72%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $33.05
Upside: +36.16%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $7.88
Upside: +103.05%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $485.36
Upside: +16.20%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.22
Upside: +309.84%
aTyr Pharma
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.90
Upside: +1,790.99%
MBX Biosciences
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $37.67
Upside: -4.43%
Kiniksa Pharmaceuticals International,
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $43.09
Upside: +25.32%
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $7.75
Upside: -22.58%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.39
Upside: +331.65%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $3.93
Upside: +78.12%
Mar 5, 2025
Initiates: Buy
Price Target: $245
Current: $272.74
Upside: -10.17%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $13.45
Upside: +93.31%
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $20.73
Upside: -66.23%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $7.83
Upside: +257.60%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $3.57
Upside: +96.08%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $79.72
Upside: +11.64%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $8.25
Upside: +203.03%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $16.85
Upside: +143.32%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $21.80
Upside: +60.55%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $56.15
Upside: +129.74%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $5.67
Upside: +41.09%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $103.59
Upside: -6.36%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $28.44
Upside: +286.78%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $4.87
Upside: +618.69%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $2.17
Upside: +314.75%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $15.52
Upside: +1,253.09%